MCM
RCUS icon

MAI Capital Management’s Arcus Biosciences RCUS Stock Holding History

MAI Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11
Closed -$238 – 4120
2026
Q1 		$238 Buy
+11
New +$238 ﹤0.01% 4584
2025
Q3 		– Sell
-242
Closed -$1.97K – 4076
2025
Q2 		$1.97K Buy
+242
New +$2.07K ﹤0.01% 3426

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

MAI Capital Management's RCUS Position: Q2 2026 in Review

MAI Capital Management sold out of Arcus Biosciences (RCUS) in Q2 2026, closing a stake of 11 shares — an estimated $238 sold.

MAI Capital Management first reported a position in RCUS in Q2 2025 and held it in 2 quarters. The position peaked at $1.97K in Q2 2025. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • MAI Capital Management reported no remaining Arcus Biosciences position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 11 Arcus Biosciences shares in Q2 2026, an estimated $238.
  • MAI Capital Management first reported a position in Arcus Biosciences in Q2 2025 and held it in 2 quarters.
  • MAI Capital Management's Arcus Biosciences position peaked at $1.97K in Q2 2025.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.